Novavax Inc (NVAX) USD0.01
Share news, reports & tips
18 February 2021 14:39
(Sharecast News) - There is still a need for the Covid-19 vaccines developed by Johnson&Johnson and Novavax, even if some of their potency is lost on the new novel coronavirus strain detected in South...
11 January 2021 12:34
(Sharecast News) - Top executives at US biotechnology company Novavax sold roughly $46m worth of the company's stock while its Covid-19 vaccine was still undergoing late stage clinical trials.
9 November 2020 14:00
(Sharecast News) - The US Food and Drug Administration has granted 'fast track' designation to Novavax's Covid-19 vaccine candidate, potentially accelerating the approval process.
25 September 2020 12:42
(Sharecast News) - Novavax has signed an agreement for Endo International to manufacture its experimental Covid-19 vaccine, which is currently in multiple phase 2 clinical trials.
14 August 2020 07:48
(Sharecast News) - US vaccine development company Novavax has agreed to supply the UK government with 60m doses of its Covid-19 vaccine, NVX-CoV2373, as early as the first quarter of 2021.
7 July 2020 11:15
(Sharecast News) - Novavax said on Tuesday that it has been awarded $1.6bn in government funding to develop its Covid-19 vaccine.
Company announcements Announcements
No company announcements about Novavax Inc USD0.01 were found.
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2021. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.